NL
STLN

NWAM LLC’s Starling Oncology STLN Stock Holding History

NWAM LLC’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,679
Closed -$24.5K – 498
2024
Q1 		$24.5K Buy
+27,679
New +$52.6K ﹤0.01% 552
2023
Q3 		– Sell
-20,000
Closed -$11K – 547
2023
Q2 		$11K Buy
+20,000
New +$10.6K ﹤0.01% 534

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return
BFM
Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC's STLN Position: Q2 2024 in Review

NWAM LLC sold out of Starling Oncology (STLN) in Q2 2024, closing a stake of 27,679 shares — an estimated $24.5K sold.

NWAM LLC first reported a position in STLN in Q2 2023 and held it in 2 quarters. The position peaked at $24.5K in Q1 2024. 39 funds tracked by Wall St. Rank hold STLN as of Q2 2024.

  • NWAM LLC reported no remaining Starling Oncology position as of Q2 2024 after selling out during the quarter.
  • NWAM LLC sold 27,679 Starling Oncology shares in Q2 2024, an estimated $24.5K.
  • NWAM LLC first reported a position in Starling Oncology in Q2 2023 and held it in 2 quarters.
  • NWAM LLC's Starling Oncology position peaked at $24.5K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2024.

Based on NWAM LLC's 13F filing for Q2 2024, filed 24 Jul 2024.